Medpace Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Medpace stock.
View analyst ratings for Medpace or view top-rated stocks.

Wall Street analysts have given Medpace a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Medpace wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Medpace is scheduled to release its next quarterly earnings announcement on Monday, October 25th 2021.
View our earnings forecast for Medpace.

Medpace will be holding an earnings conference call on Tuesday, October 26th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "5177474".

Medpace Holdings, Inc. (NASDAQ:MEDP) released its earnings results on Sunday, July, 25th. The company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.99 by $0.07. The company had revenue of $278.29 million for the quarter, compared to analyst estimates of $271.20 million. Medpace had a trailing twelve-month return on equity of 21.74% and a net margin of 17.07%.
View Medpace's earnings history.

Medpace's stock was trading at $83.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MEDP stock has increased by 128.1% and is now trading at $190.76.
View which stocks have been most impacted by COVID-19.

Medpace issued an update on its FY 2021 earnings guidance on Monday, August, 2nd. The company provided earnings per share (EPS) guidance of $4.310-$4.500 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.380. The company issued revenue guidance of $1.11 billion-$1.15 billion, compared to the consensus revenue estimate of $1.13 billion.

3 equities research analysts have issued 1 year target prices for Medpace's shares. Their forecasts range from $167.90 to $205.00. On average, they anticipate Medpace's share price to reach $190.97 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price.
View analysts' price targets for Medpace or view top-rated stocks among Wall Street analysts.

268 employees have rated Medpace CEO August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among Medpace's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Medpace include Charles River Laboratories International (CRL), Bitcoin Group (BTGGF), Exact Sciences (EXAS), PPD (PPD), Incyte (INCY), ICON Public (ICLR), Syneos Health (SYNH), Zymergen (ZY), Anavex Life Sciences (AVXL), National Research (NRC), Absci (ABSI), Inotiv (NOTV), SomaLogic (SLGC), Starpharma (SPHRY) and CM Life Sciences II (CMII).
View all of MEDP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.37%), Vanguard Group Inc. (9.01%), Wasatch Advisors Inc. (6.84%), Invesco Ltd. (2.59%), State Street Corp (2.37%) and Price T Rowe Associates Inc. MD (1.96%). Company insiders that own Medpace stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., BlackRock Inc., Eagle Asset Management Inc., FMR LLC, abrdn plc, Jupiter Asset Management Ltd., Vanguard Group Inc., and Bernzott Capital Advisors. Company insiders that have sold Medpace company stock in the last year include Ashley M Keating, August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, Susan E Burwig, and Tom C King.
View insider buying and selling activity for Medpace or view top insider-selling stocks.

MEDP stock was bought by a variety of institutional investors in the last quarter, including Echo Street Capital Management LLC, Vulcan Value Partners LLC, Goldman Sachs Group Inc., American Capital Management Inc., Dimensional Fund Advisors LP, Amundi, Epoch Investment Partners Inc., and Monarch Partners Asset Management LLC. Company insiders that have bought Medpace stock in the last two years include Peter J O'malley, and Wedbush Securities Inc.
View insider buying and selling activity for Medpace or or view top insider-buying stocks.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MEDP stock can currently be purchased for approximately $190.76.

Medpace has a market capitalization of $6.83 billion and generates $925.92 million in revenue each year. The company earns $145.38 million in net income (profit) each year or $4.00 on an earnings per share basis.

Medpace employs 3,600 workers across the globe.

The official website for Medpace is www.medpace.com.

Medpace is headquartered at 5375 MEDPACE WAY, CINCINNATI OH, 45227.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at (513) 579-9911 or via email at [email protected].